Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review

Pediatric Blood and Cancer

Volumn 60, Issue 9, 2013, Pages 1520-1527

  Mateos, Marion K ^a,b   O'Brien, Tracey A ^a,b   Oswald, Cecilia ^a   Gabriel, Melissa ^c   Ziegler, David S ^a,b   Cohn, Richard J ^a,b   Russell, Susan J ^a,b   Barbaric, Draga ^a   Marshall, Glenn M ^a,b   Trahair, Toby N ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Hematopoeitic stem cell transplant; Lymphoblastic leukemia; Outcomes; Pediatric acute survival; Transplant related mortality

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; DONOR; EVENT FREE SURVIVAL; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SCHOOL CHILD; SIBLING; TREATMENT OUTCOME;

HEMATOPOEITIC STEM CELL TRANSPLANT; LYMPHOBLASTIC LEUKEMIA; OUTCOMES; PEDIATRIC ACUTE SURVIVAL; TRANSPLANT-RELATED MORTALITY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84880341021     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24559     Document Type: Article

References (54)

1. Hunger S, Raetz E, Loh M, et al. Improving outcomes for high-risk ALL: Translating new discoveries into clinical care. Pediatr Blood Cancer 2011; 56:984-993.
2. Pui C, Carroll W, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 2011; 29:551-565.
3. Pulsipher M, Peters C, Pui C. High-risk pediatric acute lymphoblastic leukemia. To transplant or not to transplant? Biol Blood Marrow Transplant 2011; 17:s137-s148.
4. Pulsipher M, Bader P, Klingebiel T, et al. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: The emerging role of peritransplantation minimal residual disease chimerism monitoring and novel chemotherapeutic molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant 2009; 15:62-71.
5. Bader P, Kreyenberg H, Henze G, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia; The ALL-REZ BFM Study Group. J Clin Oncol 2009; 27:377-384.
6. Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002; 16:1668-1672.
7. Knechtli C, Goulden N, Hancock J, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998; 92:4072-4079.
8. Szczepanski T, Orfao A, van der Velden V, et al. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2:409-417.
9. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): An open-label randomised trial. Lancet 2010; 376:2009-2017.
10. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of the trial ALL-REZ BFM 9. J Clin Oncol 2010; 28:2339-2347.
11. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome positive acute lymphoblastic leukemia: A Children's Oncology Group Study. J Clin Oncol 2009; 27:5175-5181.
12. Peters C, Schrauder A, Schrappe M, et al. Allogeneic haematopoeitic stem cell transplantation in children with acute lymphoblastic leukaemia: The BFM/IBFM/EBMT concepts. Bone Marrow Transplant 2005; 35:s9-s11.
13. Eapen M, Rubinstein P, Zhang M, et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoeitic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 2006; 24:145-151.
14. Lanino E, Sacchi N, Peters C, et al. Strategies of the donor search for children with second CR ALL lacking a matched sibling donor. Bone Marrow Transplant 2008; 41:S75-S79.
15. Rocha V, Locatelli F. Searching for alternative hematopoeitic stem cell donors for pediatric patients. Bone Marrow Transplant 2008; 41:207-214.
16. MacMillan M, Davies S, Nelson G, et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 14:16-22.
17. Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoeitic stem cell transplantation: A retrospective analysis. Cancer 2009; 115:4715-4726.
18. Gooley T, Chien J, Pergam S, et al. Reduced mortality after allogeneic hematopoeitic-cell transplantation. N Engl J Med 2010; 363:2091-2101.
19. Slats A, Egeler R, van der Does-van denBerg A, et al. Causes of death-Other than progressive leukemia-In childhood acute lymphoblastic leukemia (ALL) and myeloid leukemia (AML): The Dutch Childhood Oncology Group experience. Leukemia 2005; 19:537-544.
20. Woolfrey A, Anasetti C, Storer B, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 2002; 99:2002-2008.
21. Shaw P, Kan F, Ahn K, et al. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood 2010; 116:4007-4015.
22. Locatelli F, Zecca M, Messina C, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoeitic stem cell transplantation from unrelated donors. Leukemia 2002; 16:2228-2237.
23. Pession A, Rondelli R, Locatelli F, et al. Role of a hematopoeitic stem cell transplant registry in childhood: The experience of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Haematologica 2002; 87:42-46.
24. Borgmann A, von Stackelberg A, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis. Blood 2003; 101:3835-3839.
25. Bunin N, Carston M, Wall D, et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 2002; 99:3151-3157.
26. Miano M, Labopin M, Hartmann O, et al. Haematopoietic stem cell transplantation trends in children over the last three decades: A survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007; 39:89-99.
27. Dini G, Cancedda R, Giorgiani G, et al. Unrelated donor marrow transplantation in childhood: A report from the Associazione Italiana Ematologia e Oncologia Pediatrica (AEIOP) and the Gruppo Italiano per il Trapianto Midollo Osseo (GITMO). Haematologica 2002; 87: 51-57.
28. Kamani N, Spellman S, Hurley C, et al. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. Biol Blood Marrow Transplant 2008; 14:1-6.
29. Hurley C, Lowe L, Logan B, et al. National marrow donor program HLA matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplant 2003; 9:610-615.
30. Ohashi K, Tanabe J, Watanabe R, et al. The Japanese Multicenter Open Randomized Trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64:32-38.
31. Qureshi A, Marshall L, Lancaster D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 2008; 50:831-832.
32. Cheuk D, Wang P, Lee T, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoeitic stem cell transplantation. Bone Marrow Transplant 2007; 40:935-944.
33. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
34. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18:295-304.
35. Eapen M, Rubinstein P, Zhang M, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: A comparison study. Lancet 2007; 369:1947-1954.
36. Rocha V, Kabbara N, Ionescu I, et al. Pediatric related and unrelated cord blood transplantation for malignant diseases. Bone Marrow Transplant 2009; 44:653-659.
37. Barrett A, Horowitz M, Pollock B, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994; 331:1253-1258.
38. Uderzo C, Valsecchi M, Balduzzi A, et al. Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. Br J Haematol 1997; 96:387-394.
39. Saarinen-Pihkala U, Gustafsson G, Ringden O, et al. No disadvantages in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 2001; 19:3406-3414.
40. Locatelli F, Rocha V, Chastang C, et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Blood 1999; 93:3662-3671.
41. Moore A, Shaw P, Hallahan A, et al. Haemotopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: A report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. Med J Aust 2009; 190:121-125.
42. Rocha V, Cornish J, Sievers E, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97:2962-2971.
43. Kurtzberg J, Prasad V, Carter S, et al. Results of the Cord Blood Transplantation Study (COBLT): Clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008; 112:4318-4327.
44. Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66:1330-1334.
45. Leung W, Pui C, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoeitic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012; 120:468-472.
46. Gratwohl A, Brand R, Niederwieser D, et al. Introduction of a quality management system and outcome after hematopoeitic stem-cell transplantation. J Clin Oncol 2011; 29:1980-1986.
47. Lee S, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching continues to the success of unrelated donor marrow transplantation. Blood 2007; 110:4576-4583.
48. Behrendt C, Rosenthal J, Bolotin E, et al. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 2009; 15:54-60.
49. Lausen B, Heilmann C, Vindelov L, et al. Outcome of acute lymphoblastic leukaemia in Danish children after allogeneic bone marrow transplantation. Superior survival following transplantation with matched unrelated donor grafts. Bone Marrow Transplant 1998; 22:325-330.
50. Boeckh M, Nichols W. The impact of cytomegalovirus serostatus of donor and recipient before hematopoeitic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 104:2003-2008.
51. Mayor N, Shaw B, Hughes D, et al. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoeitic stem-cell transplantation with unrelated donors. J Clin Oncol 2007; 25:4262-4269.
52. Ko R, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 2010; 28:648-654.
53. Carol H, Boehm I, Reynolds C, et al. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 2011; 68:1291-1304.
54. Diaz M, Gonzalez-Vicent M, Gonzalez M, et al. Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: A report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH). Bone Marrow Transplant 2005; 36:781-785.